Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

What this Trial Is About

Researchers are evaluating the use of intravenous loop diuretics, specifically 20mg of furosemide, during Holmium Laser Enucleation of the Prostate (HoLEP) for men with benign prostatic hypertrophy (BPH). HoLEP is recognized as a size-independent treatment for BPH and is recommended by the American Urological Association. The study aims to determine if giving furosemide during the morcellation phase affects the rates of same-day discharge after surgery. In this randomized, double-blind trial, participants are assigned to receive either 20mg of IV furosemide during the morcellation phase of their HoLEP procedure or no furosemide during this phase. The purpose is to compare how these two approaches influence recovery and discharge timing. Patients, surgeons, and care teams remain unaware of the group assignments to ensure unbiased results. Participants will be monitored for outcomes such as same-day discharge rates and same-day catheter removal within 90 days after surgery. Researchers will also track adverse events like hematuria and fluid absorption, operative efficiency, length of hospital stay, and overall complications. The study includes patient questionnaires and follows patients for safety and recovery over a 90-day period.

Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP